Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) — Healthcare · Share Price, Chart & Market Data
About: Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: $15.60 (-4.35%)
AMLXAmylyx Pharmaceuticals Inc
Loading watchlist status…
Trade AMLX now
Amylyx Pharmaceuticals Inc share price
AMLX price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
30 Apr, 1:46 am GMT+0
AMLX price performance
-9.931%
5D
22.257%
1M
36.602%
YTD
218.367%
1Y
AMLX price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
30 Apr, 1:46 am GMT+0
AMLX details
AMLX Market Signals